Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
pINPOINt secukinumab in plaque psoriasis with coexisting non-alcoholic fatty liver disease
2019-003168-37Phase 3Terminated
- Sponsor
- Novartis
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis and metabolic dysfunction-associated steatotic liver disease (MASLD) comparing Secukinumab with Placebo (2 arms). Primary endpoint: Proportion of patients achieving PASI90 response. Started Oct 2019; status: terminated.
02
Drugs
secukinumab
03
Conditions
plaque psoriasismetabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on 2019-003168-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003168-37.